When it comes to semaglutide, many people are familiar with its hypoglycemic and weight reducing effects, but the medical value of this GLP-1 receptor agonist has already broken through limitations, and has gained strong support from authoritative clinical trials in areas such as cardiovascular protection, kidney disease intervention, and even liver disease treatment.
As a star drug for the treatment of type 2 diabetes, Somaglutide's hypoglycemic advantage was confirmed in the SUSTAIN clinical project, which covered six phase III trials. The data of more than 8000 patients showed that its hypoglycemic effect was significantly better than that of common drugs such as sitagliptin and insulin glargine. In the field of weight loss, a phase II trial published in The Lancet showed that treatment with the highest dose of semaglutide for 52 weeks resulted in an average weight loss of 13.8% for patients, far exceeding the placebo's 2.3%.
More noteworthy is its cardiorenal protective effect. The SOUL test results published by the New England Journal of Medicine in 2025 showed that taking 14 mg of somalutide orally could reduce the risk of major cardiovascular events in patients with type 2 diabetes combined with cardiorenal disease by 14%. The FLOW test confirmed that it can reduce the composite endpoint risk of type 2 diabetes patients with chronic kidney disease by 24%, providing a new choice for the treatment of kidney disease.
Recently, semaglutide has made another breakthrough in the field of liver disease. The ESSENSE Phase 3 clinical trial showed that injecting 2.4mg of semaglutide per week reduced liver inflammation in 62.9% of MASH patients and improved liver fibrosis in 36.8% of patients. Now it has been approved by the FDA for the treatment of non cirrhotic MASH, becoming the first GLP-1 receptor agonist approved for this indication.
The pleiotropy of semaglutide has been continuously confirmed, from blood sugar lowering to cardiorenal protection, and then to liver disease intervention. These clinical trials across diabetes, obesity, cardiovascular disease and other fields make this drug an important weapon for comprehensive management of chronic diseases.
Post time: 2025-12-04